Postpartum Ovulation & Fertility Calculator

What the percentage estimates

For someone giving breastfeeds or breast milk, the percentage estimates the cumulative chance of at least one hormone-detected ovulation before first bleeding by the entered postpartum month. It is not the chance of ovulating today, pregnancy from one act, or proof of an ovulation with a fully adequate luteal phase.

Research curve and personal adjustment

The pooled study reported 30.9% by 6 months and 67.3% by 12 months. The curve is F(t) = 1 - exp(-((t / 11.1915) ^ 1.5966)), where t is postpartum months. Values before month 6 are extrapolated from the fit, and values between months 6 and 12 are interpolated. Months 13-24 extend the same curve beyond the last direct study point and are labelled PCC extrapolations. The unadjusted curve gives about 80% by 15 months, 88% by 18 months, 93% by 21 months and 97% by 24 months. No later percentage is shown.

An Australian hormone study of 89 people breastfeeding for an extended time found an average of 322 days without ovulation and a latest first ovulation at 750 days, or about 24.6 months. The fitted curve averages about 305 days and leaves a small tail after 24 months, so the study is a useful check on the extended range. It does not directly validate each extrapolated percentage.

Very frequent breastfeeding can delay ovulation much longer. A historical hormone study among the Gainj of highland New Guinea found a median of 20.4 months without ovulation, with much more frequent nursing than is usual in the United States. That population shows why timing can vary widely, but it is not used as the typical U.S. estimate.

The exact breastmilk share, night feeds, feeding method, maternal age and complication answers can shift the curve's timing by no more than 1.5 months. This bounded PCC adjustment preserves the direction expected from feeding-pattern research without allowing those answers to create an implausible near-100% result. Its coefficients are planning assumptions, not a clinically validated individual prediction. The unadjusted cohort number remains in Research detail.

The median and percentile range come from the fitted curve. The 75th percentile extends beyond the final 12-month research anchor, so it is labelled as an extrapolation.

How the other results are calculated

• Returned period-like bleeding: your entered status and date take priority. A daily hormone study found that about two-thirds of participants ovulated before their first postpartum bleeding, but early cycles often had luteal-phase defects.
• Period window: dates use cohort period-return timing. The breastfeeding median was 42 weeks with a middle-50% range of 26-50 weeks; the nonbreastfeeding median was 14 weeks with a 10-18-week range. A window that has passed is context, not a deadline.
• Pregnancy testing: if the next period date is unknown, test at least 21 days after the relevant unprotected sex. An entered first-period date can also produce an illustrative next missed-period date.
• Three-cycle planning: an entered period date uses cycle days 12-14 in illustrative 30-day cycles. Without a period date, breastfeeding dates use a conditional PCC estimate and are clearly labelled as planning estimates.
• Birth type: it stays in your result note but does not change the percentage because the cited recent cohort did not find a meaningful mode-of-delivery difference.
• Contraception: the selected method changes interpretation, not the natural-return percentage. That percentage is not a contraceptive failure estimate.

LAM check

LAM requires no returned menses, a baby under 6 months, fully or nearly fully breastfeeding, and feeding gaps no longer than 4 hours by day or 6 hours at night. Breastfeeding may keep delaying ovulation after 6 months, but the standard LAM result ends there because protection becomes less predictable. Missing gap answers produce a not-fully-assessed result without blocking the other estimates. Mostly expressed milk adds uncertainty because evidence about relying on pumping for LAM is limited.

Important limitations

• The hormone analysis was small, pooled older studies from different settings and does not fully condition on a particular user still having no bleeding today.
• Feeding and population factors affect timing, but no published model validates the exact combined personal adjustment used here. Treat personal dates and adjusted percentages as planning estimates.
• Hormonal contraception may suppress ovulation or change bleeding. The natural postpartum number stays visible for context but is not an estimate while using that method.
• No calculator can diagnose ovulation. Clinical testing, ultrasound or carefully interpreted cycle signs are needed to establish whether it occurred.

Sources

• Kennedy and Visness, 1992 - pooled hormone-detected ovulation and pregnancy during lactational amenorrhea.
• Lewis and colleagues, 1991 - hormone-detected return of ovulation in an extended-breastfeeding Australian cohort.
• Wood and colleagues, 1985 - hormonal evidence of prolonged lactational anovulation with exceptionally frequent nursing.
• Campbell and Gray, 1993 - hormone monitoring around first postpartum bleeding and early luteal-phase quality.
• WHO study I and WHO study II - variation in lactational amenorrhea and feeding-related predictors.
• CDC LAM criteria - amenorrhea, feeding pattern, age and day/night interval rules.
• CDC Selected Practice Recommendations - timing of first ovulation among nonlactating people.
• Samejima and colleagues, 2024 - breastfeeding and nonbreastfeeding period-return timing, age and mode-of-delivery context.
• NHS pregnancy-test guidance - testing from a missed period or at least 21 days after unprotected sex when cycle timing is unknown.
• ACOG postpartum birth control - ovulation before a period, LAM and pumping uncertainty.
• ACOG combined hormonal birth control and ACOG progestin-only birth control - method-specific ovulation effects.
• CDC intrauterine contraception guidance - bleeding and amenorrhea with IUD use.
• Official US prescribing information for Paragard, Nexplanon, Mirena and Depo-Provera - method-specific interpretation.